# The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure

> **NCT06027567** · PHASE4 · COMPLETED · sponsor: **Rigmor Højland Jensen** · enrollment: 38 (actual)

## Conditions studied

- Idiopathic Intracranial Hypertension
- Intracranial Pressure
- Obesity
- Pseudotumor Cerebri Syndrome
- Papilledema
- Weight Loss

## Interventions

- **DRUG:** Semaglutide
- **DIETARY_SUPPLEMENT:** Very Low Calorie Diet
- **BEHAVIORAL:** Dietician counselling

## Key facts

- **NCT ID:** NCT06027567
- **Lead sponsor:** Rigmor Højland Jensen
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-02
- **Primary completion:** 2025-01-28
- **Final completion:** 2025-10-28
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2026-02-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06027567

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06027567, "The Effect of an Anti-obesity Drug, Semaglutide, as Treatment in New-onset Idiopathic Intracranial Hypertension (IIH) Compared to Standard Weight Management (Dietician) With Regards to Change in Weight and Intracranial Pressure". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT06027567. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*